NAUT
Nautilus Biotechnology, Inc.Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-04-28 |
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Business Highlights Initiated our Iterative |
| 2026-04-09 |
Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026
SEATTLE, April 09, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter 2026 before market open on Tuesday, April 28, 2026. |
| 2026-03-24 |
Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference
SEATTLE, March 24, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Investor Summit Group Virtual Conference. |
| 2026-03-18 |
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit • NIH-funded project leverages collaborators’ expertise in single-molecule proteomics and protein isoform quantification to advance |
| 2026-03-02 |
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales
Veteran sales leader with proven proteomics and life sciences track record from Olink and SomaLogic joins Nautilus to accelerate commercial progress of its Voyager Platform SEATTLE, March 02, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering single-molecule |
| 2026-02-26 |
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results
SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. |
| 2026-02-24 |
Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026
• Revealed core proteomics instrument during US HUPO 2026 following successful field evaluation at the Buck Institute for Research on Aging • Commercial launch expected to initiate in late 2026, marking a major milestone for next-generation proteomics • Researchers invited to apply to the Early |
| 2026-02-19 |
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 46 th Annual Health Care Conference. |
| 2026-02-05 |
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year 2025 before market open on Thursday, |
| 2026-01-28 |
Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease
• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’ development of a single-molecule assay for measuring alpha-synuclein proteoforms is its latest application of Iterative Mapping method to uncover new |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-05-21 | Alliance Global Partners' Annual Virtual Healthcare Conference | Conference |
| 2026-04-28 | Nautilus Q1 2026 Earnings Conference Call | Earnings call |
| 2026-03-25 | Q1 Investor Summit Group Virtual Conference | Conference |
| 2026-03-02 | TD Cowen 46th Annual Health Care Conference | Conference |
| 2026-02-26 | Nautilus Q4 and FY 2025 Earnings Conference Call | Earnings call |
| 2025-10-28 | Nautilus Q3 2025 Earnings Conference Call | Earnings call |
| 2025-09-16 | Q3 Investor Summit Group Virtual Conference | Conference |
| 2025-09-08 | Morgan Stanley 23rd Annual Global Healthcare Conference | Conference |
| 2025-07-31 | Nautilus Q2 2025 Earnings Conference Call | Earnings call |
| 2025-06-10 | Goldman Sachs 46th Annual Global Healthcare Conference | Conference |
Source: https://investors.nautilus.bio/